新闻中心

驯鹿生物简介

驯鹿生物是一家立足中国、服务于全球患者的致力于细胞创新药物研发、生产和销售的生物制药公司。 公司以开发血液肿瘤细胞治疗类药物和抗体药物为创新基石,向自身免疫疾病治疗领域拓展,拥有完整的从早期发现、临床开发、注册申报到商业化生产的全流程能力。 公司自行开发的五大技术平台包括全人源抗体开发平台、免疫细胞药物开发平台、全流程生产及检定技术平台、药理药效平台及临床开发平台。 公司现有10余个在研品种处于不同研发阶段,其中伊基奥仑赛已获中国药监局(NMPA)批准上市,并纳入“突破性治疗药物”品种。 同时获得美国FDA批准注册临床,用于治疗复发/难治多发性骨髓瘤,荣获FDA授予“孤儿药(ODD)”认定及再生医学先进疗法(RMAT)和快速通道(FT)资格。
查看详情

完全缓解率82.4%!驯鹿生物在2023年国际骨髓瘤学会(IMS)年会壁报展示BCMA

2023年9月28日,中国南京、上海,加州圣荷西——驯鹿生物,一家致力于细胞创新药物研发、生产和销售的生物制药公司, 与信达生物制药集团(香港联交所股票代码:01801),一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司, 在2023年国际骨髓瘤学会(IMS)年会以壁报报告形式展示了两项研究成果: (1)全人源自体B细胞成熟抗原(BCMA)嵌合抗原受体自体T细胞(CAR-T)疗法伊基奥仑赛注射液治疗复发/难治性多发性骨髓瘤(RRMM) 1b/2期研究(FUMANBA-1)的最新长期随访结果(摘要编号P-290);(2)预测复发/难治性多发性骨髓瘤患者在抗BCMA CAR-T治疗后血小板减少恢复时间延长的风险模型 分析(摘要编号P-288)。
查看详情

驯鹿生物与信达生物共同宣布全球首个全人源靶向BCMA CAR-T产品福可苏®

2023年7月3日,中国南京、上海,加州圣荷西 ——驯鹿生物, 一家致力于细胞创新药物研发、生产和销售的生物制药公司,与信达生物制药集团(香港联交所股票代码:01801), 一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司, 共同宣布国家药品监督管理局已正式批准双方共同开发及商业化的细胞免疫治疗产品福可苏®(伊基奥仑赛注射液, 驯鹿生物研发代号:CT103A;信达生物研发代号:IBI326)的新药上市申请(NDA),用于治疗复发难治多发性骨髓瘤成人患者, 既往经过至少3线治疗后进展(至少使用过一种蛋白酶体抑制剂及免疫调节剂)。
查看详情
1 2 3

新闻中心

驯鹿生物简介

驯鹿生物是一家立足中国、服务于全球患者的致力于细胞创新药物研发、生产和销售的生物制药公司。 公司以开发血液肿瘤细胞治疗类药物和抗体药物为创新基石,向自身免疫疾病治疗领域拓展,拥有完整的从早期发现、临床开发、注册申报到商业化生产的全流程能力。 公司自行开发的五大技术平台包括全人源抗体开发平台、免疫细胞药物开发平台、全流程生产及检定技术平台、药理药效平台及临床开发平台。 公司现有10余个在研品种处于不同研发阶段,其中伊基奥仑赛已获中国药监局(NMPA)批准上市,并纳入“突破性治疗药物”品种。 同时获得美国FDA批准注册临床,用于治疗复发/难治多发性骨髓瘤,荣获FDA授予“孤儿药(ODD)”认定及再生医学先进疗法(RMAT)和快速通道(FT)资格。
查看详情

完全缓解率82.4%!驯鹿生物在2023年国际骨髓瘤学会(IMS)年会壁报展示BCMA

2023年9月28日,中国南京、上海,加州圣荷西——驯鹿生物,一家致力于细胞创新药物研发、生产和销售的生物制药公司, 与信达生物制药集团(香港联交所股票代码:01801),一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司, 在2023年国际骨髓瘤学会(IMS)年会以壁报报告形式展示了两项研究成果: (1)全人源自体B细胞成熟抗原(BCMA)嵌合抗原受体自体T细胞(CAR-T)疗法伊基奥仑赛注射液治疗复发/难治性多发性骨髓瘤(RRMM) 1b/2期研究(FUMANBA-1)的最新长期随访结果(摘要编号P-290);(2)预测复发/难治性多发性骨髓瘤患者在抗BCMA CAR-T治疗后血小板减少恢复时间延长的风险模型 分析(摘要编号P-288)。
查看详情

驯鹿生物与信达生物共同宣布全球首个全人源靶向BCMA CAR-T产品福可苏®

2023年7月3日,中国南京、上海,加州圣荷西 ——驯鹿生物, 一家致力于细胞创新药物研发、生产和销售的生物制药公司,与信达生物制药集团(香港联交所股票代码:01801), 一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司, 共同宣布国家药品监督管理局已正式批准双方共同开发及商业化的细胞免疫治疗产品福可苏®(伊基奥仑赛注射液, 驯鹿生物研发代号:CT103A;信达生物研发代号:IBI326)的新药上市申请(NDA),用于治疗复发难治多发性骨髓瘤成人患者, 既往经过至少3线治疗后进展(至少使用过一种蛋白酶体抑制剂及免疫调节剂)。
查看详情
1 2 3
医务人员支持
医务人员支持

福可苏®治疗过程

福可苏®与传统的癌症治疗方法(如化疗、放疗等)有显著区别。该疗法利用从您自身血液中提取的T细胞,通过基因改造将靶向B细胞成熟抗原(BCMA)的嵌合抗原受体(CAR)基因整合到分离出的T细胞中。 这一创新方法使得福可苏®能够准确识别和攻击体内的多发性骨髓瘤细胞,提供了独特的治疗途径。

作为一种定制化治疗,您需要前往获得认证的治疗中心,由专业医疗团队为您开具处方并进行药物输注。您的医疗团队将全程协助您进行详细的咨询和评估,以帮助您了解是否适合接受福可苏®治疗。

治疗过程

福可苏®治疗过程

福可苏®与传统的癌症治疗方法(如化疗、放疗等)有显著区别。该疗法利用从您自身血液中提取的T细胞,通过基因改造将靶向B细胞成熟抗原(BCMA)的嵌合抗原受体(CAR)基因整合到分离出的T细胞中。 这一创新方法使得福可苏®能够准确识别和攻击体内的多发性骨髓瘤细胞,提供了独特的治疗途径。

作为一种定制化治疗,您需要前往获得认证的治疗中心,由专业医疗团队为您开具处方并进行药物输注。您的医疗团队将全程协助您进行详细的咨询和评估,以帮助您了解是否适合接受福可苏®治疗。

治疗过程
手册1
点击查看
手册2
点击查看
手册3
点击查看
手册1
点击查看
手册2
点击查看
手册3
点击查看

活动回顾

活动1
活动2
活动3
活动4

活动回顾

活动1
活动2
活动3
活动4

News Center

IASO Bio Profile

IASO Bio is a biopharmaceutical company engaged in discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput chimeric antigen receptor T-cell (CAR-T) drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This pipeline includes a portfolio of over 10 novel products, including FUCASO® (eque-cel ). Eque-cel received New Drug Application (NDA) approval from China's National Medical Products Administration (NMPA) and U.S. FDA IND approval for the treatment of R/R MM. IASO also received Breakthrough Therapy Designation (BTD) from the NMPA in February 2021 and Orphan Drug Designation (ODD) from the FDA in February 2022, Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations from the FDA in February 2023.
Explore more

IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T

SHANGHAI, NANJING, CHINA, AND SAN JOSE, Calif., September 28, 2023 - IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, today announced updated long-term follow-up data from two studies for BMCA CAR-T: (1) Results from phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with Equecabtagene Autoleucel (IASO Bio R&D code: CT103A, Innovent R&D code: IBI326, Abstract Code P-290) and (2) A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T Treatment (Abstract Code P-288) at the 2023 International Myeloma Society (IMS) Annual Meeting in Vienna on September 27-30, 2023.
Explore more

IASO Bio and Innovent Announce the NMPA Approval of the NDA for

SHANGHAI, NANJING, CHINA, AND SAN JOSE, Calif., July 3, 2023 - IASO Biotechnology (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, today announced that China National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel, co-developed and co-commercialized by IASO Bio and Innovent, IASO Bio R&D code: CT103A, Innovent R&D code: IBI326), the world’s first fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent.
Explore more
1 2 3

News Center

IASO Bio Profile

IASO Bio is a biopharmaceutical company engaged in discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput chimeric antigen receptor T-cell (CAR-T) drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This pipeline includes a portfolio of over 10 novel products, including FUCASO® (eque-cel ). Eque-cel received New Drug Application (NDA) approval from China's National Medical Products Administration (NMPA) and U.S. FDA IND approval for the treatment of R/R MM. IASO also received Breakthrough Therapy Designation (BTD) from the NMPA in February 2021 and Orphan Drug Designation (ODD) from the FDA in February 2022, Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations from the FDA in February 2023.
Explore more

IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T

SHANGHAI, NANJING, CHINA, AND SAN JOSE, Calif., September 28, 2023 - IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, today announced updated long-term follow-up data from two studies for BMCA CAR-T: (1) Results from phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with Equecabtagene Autoleucel (IASO Bio R&D code: CT103A, Innovent R&D code: IBI326, Abstract Code P-290) and (2) A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T Treatment (Abstract Code P-288) at the 2023 International Myeloma Society (IMS) Annual Meeting in Vienna on September 27-30, 2023.
Explore more

IASO Bio and Innovent Announce the NMPA Approval of the NDA for

SHANGHAI, NANJING, CHINA, AND SAN JOSE, Calif., July 3, 2023 - IASO Biotechnology (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, today announced that China National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel, co-developed and co-commercialized by IASO Bio and Innovent, IASO Bio R&D code: CT103A, Innovent R&D code: IBI326), the world’s first fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent.
Explore more
1 2 3

Fucaso® Treatment Process

FUCASO® is a chimeric antigen receptor (CAR) T cell therapy—a treatment for multiple myeloma (MM) unlike anything you may have received before. FUCASO® changes your own T cells to recognize and attack a target on the surface of multiple myeloma cells and certain other healthy cells after a single infusion. The entire treatment process generally takes several months.
Treatment process

Fucaso® Treatment Process

FUCASO® is a chimeric antigen receptor (CAR) T cell therapy—a treatment for multiple myeloma (MM) unlike anything you may have received before. FUCASO® changes your own T cells to recognize and attack a target on the surface of multiple myeloma cells and certain other healthy cells after a single infusion. The entire treatment process generally takes several months.
Treatment process
manual one
Click to view
manual two
Click to view
manual three
Click to view
manual one
Click to view
manual two
Click to view
manual three
Click to view

Activities

Activities one
Activities two
Activities three
Activities four

Activities

Activities one
Activities two
Activities three
Activities four